Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 16, 2023
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
[ Wed, Aug 16th 2023
] - WOPRAI
Jonathan Wolleben Maintained (SPRB) at Buy with Increased Target to $8 on, Aug 16th, 2023
Jonathan Wolleben of JMP Securities, Maintained "Spruce Biosciences, Inc." (SPRB) at Buy with Increased Target from $7 to $8 on, Aug 16th, 2023.
Jonathan has made no other calls on SPRB in the last 4 months.
There are 4 other peers that have a rating on SPRB. Out of the 4 peers that are also analyzing SPRB, 0 agree with Jonathan's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Jonathan
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Tuesday, August 15th, 2023
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $10 on, Tuesday, June 13th, 2023
- Hartaj Singh of "Oppenheimer" Reiterated at Buy and Held Target at $8 on, Tuesday, May 23rd, 2023
- Tiago Fauth of "Credit Suisse" Reiterated at Buy and Held Target at $4 on, Tuesday, May 16th, 2023
